Vaxcyte, Inc. (PCVX)
PCVX moved a median of +0.19% 30 minutes after news, and +0.11% by the close. How PCVX actually reacts to news — the realized, point-in-time move the market made, measured across 488 labeled events over the last three years with zero look-ahead.
PCVX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.01% | 48% | 487 |
| 30-min | +0.19% | 54% | 487 |
| 60-min | +0.24% | 54% | 487 |
| to close | +0.11% | 53% | 488 |
| Middle 50% of PCVX reactions | -0.72% to +1.25% |
|---|---|
| Median reaction (30-min) | +0.19% |
| Measured reactions | 488 |
Half of all Vaxcyte, Inc. news events land between -0.72% and +1.25% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How PCVX reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 13 | +1.09% | 54% | +0.13% |
| Rating reiterations | 57 | -0.17% | 46% | -0.57% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 4 further classes were observed with fewer than 10 measured events and are not published. See how PCVX ranks against every other measured name →
That’s how PCVX usually reacts — get an email when it moves on news →Email me when PCVX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to PCVX's baseline. Nothing else.
Recent PCVX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K Vaxcyte, Inc. For: Oct 06 | SEC filing · Form 8-K | SEC EDGAR | +0.17% | -0.28% | |
| Vaxcyte Announces Closing of $1.15 Billion Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes, Including Full Exercise of Underwriters’ Options to Purchase Additional Shares and Convertible Senior Notes | Press release | GlobeNewswire | +0.17% | -0.28% | |
| Form 305B2 Vaxcyte, Inc. | SEC filing · Form 305B2 | SEC EDGAR | -8.30% | -9.07% | |
| Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes | Press release | GlobeNewswire | -0.67% | +1.78% | |
| Form 8-K Vaxcyte, Inc. For: Oct 05 | SEC filing · Form 8-K | SEC EDGAR | +2.03% | -14.89% | |
| Vaxcyte Announces Commencement of Proposed Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes | Press release | GlobeNewswire | -8.30% | -9.07% | |
| Vaxcyte Reports Positive Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate | Press release | GlobeNewswire | +2.03% | -14.89% | |
| Vaxcyte to Host Webcast and Conference Call to Present Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate | Press release | GlobeNewswire | +2.03% | -14.89% | |
| Form 8-K Vaxcyte, Inc. For: Aug 31 | SEC filing · Form 8-K | SEC EDGAR | +0.46% | +2.39% | |
| Vaxcyte Appoints Chief Medical Officer and Chief Legal Officer; Narrows Guidance for Expected VAX-31 OPUS-1 Topline Data | Press release | GlobeNewswire | +0.46% | +2.39% | |
| Vaxcyte to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | -0.20% | -2.01% | |
| Form 10-Q Vaxcyte, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +3.45% | +6.74% | |
| Form 8-K Vaxcyte, Inc. For: Aug 05 | SEC filing · Form 8-K | SEC EDGAR | +3.45% | +6.74% | |
| Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update | Press release | GlobeNewswire | +3.45% | +6.74% | |
| Form 8-K Vaxcyte, Inc. For: Jul 13 | SEC filing · Form 8-K | SEC EDGAR | -0.03% | -0.14% | |
| Vaxcyte to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +0.71% | +1.73% | |
| Form 8-K Vaxcyte, Inc. For: Jun 17 | SEC filing · Form 8-K | SEC EDGAR | +1.09% | +3.84% | |
| Form 8-K Vaxcyte, Inc. For: Jun 15 | SEC filing · Form 8-K | SEC EDGAR | +0.87% | +2.67% | |
| Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults | Press release | GlobeNewswire | -0.76% | -1.20% | |
| Form 10-Q Vaxcyte, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -6.04% | -6.42% | |
| Form 8-K Vaxcyte, Inc. For: May 06 | SEC filing · Form 8-K | SEC EDGAR | -6.04% | -6.42% | |
| Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update | Press release | GlobeNewswire | -6.04% | -6.42% | |
| Form ARS Vaxcyte, Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.51% | -1.90% | |
| Form DEF 14A Vaxcyte, Inc. For: Jun 15 | SEC filing · Form DEF | SEC EDGAR | +0.51% | -1.90% | |
| Form DEFA14A Vaxcyte, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +0.51% | -1.90% | |
| Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference | Press release | GlobeNewswire | -0.91% | -3.62% | |
| Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults | Press release | GlobeNewswire | +0.67% | +1.54% | |
| Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate | Press release | GlobeNewswire | -0.74% | -0.53% | |
| Form 10-K Vaxcyte, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +6.91% | +9.12% | |
| Form 8-K Vaxcyte, Inc. For: Feb 24 | SEC filing · Form 8-K | SEC EDGAR | +6.91% | +9.12% | |
| Form S-8 Vaxcyte, Inc. | SEC filing · Form S-8 | SEC EDGAR | +6.91% | +9.12% | |
| Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | +6.91% | +9.12% | |
| Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines | Press release | GlobeNewswire | -0.65% | +0.53% | |
| Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026 | Press release | GlobeNewswire | +0.14% | +0.43% | |
| Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit | Press release | GlobeNewswire | -0.01% | +1.79% | |
| Form 8-K Vaxcyte, Inc. For: Jan 29 | SEC filing · Form 8-K | SEC EDGAR | -0.04% | -3.56% | |
| Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares | Press release | GlobeNewswire | -0.04% | -3.56% | |
| Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants | Press release | GlobeNewswire | -4.09% | -3.50% | |
| Vaxcyte Announces Pricing of $550 Million Public Offering | Press release | GlobeNewswire | -4.09% | -3.50% | |
| Vaxcyte Advances Adult and Infant Programs for VAX-31, a Potential Best-in-Class, Next-Generation Pneumococcal Conjugate Vaccine | Press release | GlobeNewswire | +1.21% | -1.90% | |
| Form 8-K Vaxcyte, Inc. For: Dec 18 | SEC filing · Form 8-K | SEC EDGAR | +3.07% | +1.84% | |
| Vaxcyte Doses First Participants in the OPUS Phase 3, Noninferiority Trial Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults | Press release | GlobeNewswire | -1.23% | -3.53% | |
| Form 10-Q Vaxcyte, Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +1.12% | -1.47% | |
| Form 8-K Vaxcyte, Inc. For: Nov 04 | SEC filing · Form 8-K | SEC EDGAR | +1.12% | -1.47% | |
| Vaxcyte Reports Third Quarter 2025 Financial Results and Provides Business Update Including Final Data from Positive VAX-24 Infant Phase 2 Dose-Finding Study | Press release | GlobeNewswire | +1.12% | -1.47% | |
| Form 8-K Vaxcyte, Inc. For: Sep 24 | SEC filing · Form 8-K | SEC EDGAR | +0.10% | +4.68% | |
| Tentarix Biotherapeutics Strengthens Executive Team | Press release | Business Wire | +0.10% | +4.68% | |
| Vaxcyte to Establish Fill-Finish Manufacturing in North Carolina as Key Element of Long-Term United States Commercial Supply Strategy Representing Up to $1 Billion in Manufacturing and Services | Press release | GlobeNewswire | +0.10% | +4.68% | |
| Vaxcyte Advances VAX-31 Infant Phase 2 Dose-Finding Study with First Participants Receiving VAX-31 Optimized Dose | Press release | GlobeNewswire | -0.79% | +3.08% | |
| Form 10-Q Vaxcyte, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +2.16% | -0.17% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the PCVX section they belong to.
Where else PCVX is measured.
PCVX earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Vaxcyte, Inc.'s median reaction calculated?
Every labeled PCVX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 488 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 54% of PCVX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does PCVX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.